After August 17, 2026, Novus Biologicals products and services will no longer be available on this website; you will access all products and services on rndsystems.com. Create your R&D Systems online account today.
HAF016). A specific band was detected for beta -Synuclein at approximately 19 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 8." class="big_lightbox" target="_blank">
Alpha synuclein is an abundant 140 amino acid neuronal protein, expressed primarily at presynaptic terminals in the central nervous system. Alpha synuclein has been associated with several neurodegenerative diseases. A point mutation in the gene coding for the alpha-synuclein protein was the first discovery linking this protein to a rare familial form of Parkinson's disease (PD). Subsequently, other mutations in the alpha-synuclein gene have been identified in familial PD. The aggregated proteinaceous inclusions called Lewy bodies found in PD and cortical Lewy body dementia (LBD) were discovered to be predominantly alpha-synuclein. Aberrant aggregation of alpha-synuclein has been detected in an increasing number of neurodegenerative diseases, collectively known as synucleopathies. Alpha-synuclein exists physiologically in both soluble and membrane-bound states, in unstructured and alpha-helical conformations, respectively. The physiological function of alpha-synuclein appears to require its translocation between these subcellular compartments and interconversion between the 2 conformations. Abnormal processing of alpha-synuclein is predicted to lead to pathological changes in its binding properties and function (1).
![Western Blot beta-Synuclein Antibody [Unconjugated]](http://images.novusbio.com/images/antibody/Synuclein-beta_AF5528_Western_Blot_5746.jpg)
![Immunohistochemistry beta-Synuclein Antibody [Unconjugated]](http://images.novusbio.com/images/antibody/Synuclein-beta_AF5528_Immunohistochemistry_7340.jpg)
